S. 150 118th Congress
Affordable Prescriptions for Patients Act of 2023
Latest action, Jul 15, 2024: Held at the desk.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
8 cosponsors
Sponsored by John Cornyn (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
4 D · 4 R
- Democrat
- Republican
- Independent
Referred to: Senate: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
AMGEN
THE NICKLES GROUP, LLC
8 reports
8 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
8 reports
8 reports
FRESENIUS KABI USA LLC
WEST FRONT STRATEGIES LLC
8 reports
GENENTECH, INC.
MARSHALL & POPP, LLC
8 reports
8 reports
8 reports
8 reports
8 reports
All 25 of 72 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 8 | $24.8M | Q1 2023 | Q3 2024 | yes | |
| AMERICAN INTELLECTUAL PROPERTY LAW ASSOCIATION (AIPLA) | 8 | $30K | Q1 2023 | Q3 2024 | yes | |
| AMGEN | THE NICKLES GROUP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| AMGEN INC | 8 | $22.9M | Q1 2023 | Q3 2024 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| BIOTECHNOLOGY INNOVATION ORGANIZATION | 8 | $15.7M | Q1 2023 | Q3 2024 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 8 | $13.3M | Q1 2023 | Q3 2024 | yes | |
| CHAMBER OF COMMERCE OF THE U.S.A. | 8 | $142.2M | Q1 2023 | Q3 2024 | yes | |
| CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 8 | $1.3M | Q1 2023 | Q3 2024 | yes | |
| FRESENIUS KABI USA LLC | WEST FRONT STRATEGIES LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| GENENTECH, INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| GSK (FKA GLAXOSMITHKLINE INC.) | 8 | $9.9M | Q1 2023 | Q3 2024 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 8 | $14.6M | Q1 2023 | Q3 2024 | yes | |
| MERCK & CO INC | 8 | $19.2M | Q1 2023 | Q3 2024 | yes | |
| NATIONAL MULTIPLE SCLEROSIS SOCIETY | 8 | $551K | Q1 2023 | Q3 2024 | yes | |
| NOVO NORDISK INC. | 8 | $9.5M | Q1 2023 | Q3 2024 | yes | |
| PFIZER, INC. | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) | RED+BLUE STRATEGIES | 8 | $560K | Q1 2023 | Q3 2024 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 8 | $58.1M | Q1 2023 | Q3 2024 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | 8 | $480K | Q1 2023 | Q3 2024 | yes |
| TEVA PHARMACEUTICALS USA INC | 8 | $4.4M | Q1 2023 | Q3 2024 | yes | |
| TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF ELI LILLY AND COMPANY) | TIBER CREEK GROUP | 8 | $640K | Q1 2023 | Q3 2024 | yes |
| TRAVERE THERAPEUTICS | 8 | $1.1M | Q1 2023 | Q3 2024 | yes | |
| VIATRIS INC | WEST FRONT STRATEGIES LLC | 8 | $0 | Q1 2023 | Q3 2024 | yes |